The main objectives of the present study consisted in determining: (a) the sensitivity of ovarian cancer cell lines and particularly of those chemoresistant, as well as of primary ovarian cancer cells, to LBW242-mediated apoptosis; (b) whether the treatment with LBW242 sensitizes ovarian cancer cells to TRAIL-mediated apoptosis; (c) whether LBW242 potentiates the cytotoxic effects of some anticancer drugs used in the treatment of ovarian cancer. Here, TNFSF10 is linked to ovarian carcinoma.